Skip to main content
A scary good deal on trusted journalism
Get full digital access to globeandmail.com
$0.99
per week for 24 weeks SAVE OVER $140
OFFER ENDS OCTOBER 31
A scary good deal on trusted journalism
$0.99
per week
for 24 weeks
SAVE OVER $140
OFFER ENDS OCTOBER 31
// //

Kala Pharmaceuticals Inc NASDAQ: KALA-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

More stories below advertisement

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August

GlobeNewswire - Wed Aug 4, 7:00AM CDT

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in August.

2021 Wedbush PacGrow Healthcare Virtual Conference

Date: Wednesday, August 11, 2021

Todd Bazemore, Chief Operating Officer, will participate in a panel discussion titled, "Goldeneye: Next-generation ophthalmology treatments with a focus on dry eye, more potent pan-VEGF inhibition and less invasive dosing for wet AMD," at 9:45 a.m. ET.

H.C. Wainwright Opthalmology Virtual Conference

Date: Tuesday, August 17, 2021

A pre-recorded presentation will be made available beginning Tuesday, August 17, 2021 at 7:00 a.m. ET. Additionally, Kim Brazzell, Ph.D., Chief Medical Officer, will participate in a panel discussion titled, "Emerging Therapeutics for Dry Eye Disease," at 2:00 p.m. ET.

To access a webcast and subsequent archived recording of the H.C. Wainwright podium presentation, please visit "Events" in the "Investors" section of the Kala website at http://kalarx.com.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY(R) mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS(R) (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS(R) (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Investor Contacts:

Jill Steier

jill.steier@kalarx.com

781-996-5252

Hannah Deresiewicz

hannah.deresiewicz@sternir.com

212-362-1200

https://ml.globenewswire.com/media/5f67dbbe-a452-4bb8-ad6c-c360d330b8c8/small/kala-logo-cmyk-png.png

https://ml.globenewswire.com/media/5f67dbbe-a452-4bb8-ad6c-c360d330b8c8/small/kala-logo-cmyk-png.png

comtex tracking

COMTEX_390921191/2010/2021-08-04T08:00:01

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies